TRANYLCYPROMINE SULFATE (tranylcypromine sulfate) by PharmaIN is understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (cns) resulting from its irreversible inhibition of the enzyme monoamine oxidase (mao). Approved for major depressive disorder (mdd) in adult patients, drug interactions, the need for dietary restrictions (,. First approved in 2006.
Drug data last refreshed 18h ago
understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
Worked on TRANYLCYPROMINE SULFATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.